WOODCLIFF LAKE, N.J., March 10, 2021 /PRNewswire/ — Eisai will present two abstracts at the virtual Society of Gynecologic Oncology (SGO) 2021 Annual Meeting on Women’s Cancer, March 19-25 (#SGOMtg). These investigational data include the first presentation of efficacy and safety results from the KEYNOTE-775/Study 309 study, a multi-center, randomized, open-label, Phase 3 trial (NCT03517449) evaluating KEYTRUDA in combination with LENVIMA in certain patients with advanced endometrial cancer following at least one prior platinum-based regimen versus chemotherapy (treatment of physician’s choice [TPC] of doxorubicin or paclitaxel) (Plenary Session ID # 10191) in the Scientific Plenary I: Innovation and Progress in Gynecologic Oncology session. Eisai and Merck previously announced that the KEYTRUDA plus LENVIMA arm met the trial’s dual primary endpoints of progression-free survival (PFS) and overall survival (OS), as well as the secondary endpoint of objective response rate (ORR).
Additional data to be presented in the Focused Plenary V: Ovary – Time to Return to the Drawing Board session include an abstract (Plenary Session ID # 10240) on results from a randomized, double-blind, placebo-controlled, Phase 2 study evaluating the efficacy and safety of farletuzumab in combination with carboplatin plus paclitaxel or carboplatin plus pegylated liposomal doxorubicin in women with low CA125 platinum-sensitive ovarian cancer (NCT02289950). Farletuzumab (MORAb-003) is an…
